Literature DB >> 10825370

Expression of survivin and Bcl-2 in the normal human endometrium.

R Konno1, H Yamakawa, H Utsunomiya, K Ito, S Sato, A Yajima.   

Abstract

Survivin is a novel inhibitor of apoptosis. It has been reported that survivin is expressed during fetal development and in cancer tissues, but its expression has not been reported in adult tissues. We investigated the expression of survivin in the endometria of women with regular menstrual cycles using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry, and compared these findings with Bcl-2, an apoptosis inhibitor. Survivin mRNA was detected by RT-PCR in all samples (nine of nine) of endometrium during the secretory phase, but in only four out of seven samples from endometrium during the proliferative phase, and in none of the atrophic endometrium. Immunohistochemistry demonstrated a survivin protein expression that was strongest in the nuclei of glandular epithelial cells during the late secretory phase. In the proliferative phase, glandular epithelial cells were not stained for survivin. The cyclic changes of survivin and Bcl-2 showed an inverse relationship, with Bcl-2 expression being strongest in the proliferative phase and survivin expression being strongest in the secretory phase. The up-regulation of survivin expression may be due to the concurrent rise in progesterone concentrations during the normal menstrual cycle. Moreover, survivin could play an important role independent of Bcl-2 in physiological homeostasis in the normal endometrium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825370     DOI: 10.1093/molehr/6.6.529

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  49 in total

1.  Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis.

Authors:  Marzia Pennati; Gennaro Colella; Marco Folini; Lorenzo Citti; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Expression of survivin in early villus and decidua and its implication.

Authors:  Hongfa Li; Jing Yang; Yongyu Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

3.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

4.  The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Authors:  Hiromi Imamichi; Richard A Lempicki; Joseph W Adelsberger; Rebecca B Hasley; Alice Rosenberg; Gregg Roby; Catherine A Rehm; Amy Nelson; Sonya Krishnan; Mark Pavlick; Christian J Woods; Michael W Baseler; H Clifford Lane
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

Review 5.  Role of the Survivin gene in pathophysiology.

Authors:  Fengzhi Li; Michael G Brattain
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

6.  Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues.

Authors:  B Spaulding; D Pan; A Ghadersohi; G Nielsen; S Jensen; F Gellert; X Ling; M Zhang; A Black; F Li
Journal:  Histopathology       Date:  2006-12       Impact factor: 5.087

7.  Survivin expressions in human hepatoma HepG2 cells exposed to ionizing radiation of different LET.

Authors:  Xiao-Dong Jin; Li Gong; Chuan-Ling Guo; Ji-Fang Hao; Wei Wei; Zhong-Ying Dai; Qiang Li
Journal:  Radiat Environ Biophys       Date:  2008-03-14       Impact factor: 1.925

8.  The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney.

Authors:  Philipp Lechler; Xiaoqing Wu; Wanja Bernhardt; Valentina Campean; Susanne Gastiger; Thomas Hackenbeck; Bernd Klanke; Alexander Weidemann; Christina Warnecke; Kerstin Amann; Dirk Engehausen; Carsten Willam; Kai-Uwe Eckardt; Franz Rödel; Michael Sean Wiesener
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

9.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

10.  MiR-195 inhibits proliferation and growth and induces apoptosis of endometrial stromal cells by targeting FKN.

Authors:  Yun Wang; Hong Chen; Yonglun Fu; Ai Ai; Songguo Xue; Qifeng Lyu; Yanping Kuang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.